Tech Company Financing Transactions
Evommune Funding Round
Evommune, operating out of Palo Alto, received $7.5 million from Verition Fund Management.
Transaction Overview
Company Name
Announced On
6/28/2023
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series B
Investors
Verition Fund Management (Lead Investor)
Proceeds Purpose
The company intends to use funds to expand operations and its business reach.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Palo Alto, CA Undisclosed
USA
Palo Alto, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future. Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem--addressing symptom control rather than the root cause of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Luis Peña
Chief Financial Officer
Kyle Carver
Chief Medical Officer
Eugene Bauer
Chief Scientific Officer
Jeegar Patel
Browse more venture capital transactions:
Prev: 6/28/2023: Gigaroo venture capital transaction
Next: 6/28/2023: Nothing venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs